Xencor | XNCR - Equity Capital And Reserves


Xencor reported $635.59M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amgen USD 8.66B 961M Dec/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Cytokinetics USD -659.62M 138.5M Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
J&J USD 78.47B 0 Sep/2025
Karyopharm Therapeutics USD -269.26M 30.33M Sep/2025
MacroGenics USD 67M 20.38M Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Novartis USD 44.75B 2.7B Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Xencor USD 635.59M 10.27M Dec/2025